Clinical guidelineUpdated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document∗
Cited by (0)
Grants have been provided to the ARC Board including representatives of Cardialysis, the Cardiovascular Research Foundation, Duke Clinical Research Institute, and Harvard Clinical Research Institute to cover the costs of travel, meeting rooms, and lodging for academic attendees at the Washington and Rotterdam meetings by Abbott Vascular, Boston Scientific, Direct Flow Medical, Edwards Lifesciences, Heart Leaflet Technologies, Medtronic Corporation, and St. Jude Medical.
Disclosures: N. Piazza has received consultancy fees from Medtronic, his institution has received grants/grants pending from Medtronic. E.H. Blackstone has received study support from Edwards Lifesciences consultancy fees from Edwards Lifesciences. D.J. Cohen has received consultancy fees from Medtronic, his institution has received grants/grants pending from Medtronic and Edwards Lifesciences. G.A van Es is an employee of Cardialysis BV, The Netherlands. M.W. Krucoff has received study support from Edwards Lifesciences. S. Kodali is a Board member of St. Jude Medical and Thubrikar Aortic Valve and has received consultancy fees from Medtronic and Edwards Lifesciences. R. Mehran has received consultancy fees from Astra Zeneca, Janssen (Johnson & Johnson), Regado, Abbott Laboratories, Merck Sharpe & Dohme Corp., Maya Medical. Her institution has received grants/grants pending from BMS/Sanofi, The Medicines Company, Lilly/Daiichi Sanko. J. Rodés-Cabau has received consultancy fees from Edwards Lifesciences, St. Jude Medical. J.G. Webb has received consultancy fees from Edwards Lifesciences, his institution has received grants/grants pending from Edwards Lifesciences. S. Windecker has received speakers bureaus fees from Edwards Lifesciences and Medtronic, his institution has received a Swiss National Science Foundation Grant (32003B_135807) and has grants/ grants pending from Edwards Lifesciences and Medtronic. M.B. Leon is on the advi-sory Board for Edwards Lifesciences. The others authors have declared to have no conflict of interests for this paper. The VARC meetings involved members of the Interventional Cardiology Devices Branch, of the Office of Device Evaluation, Center for Devices and Radiological Health, USFDA. The opinions or assertions herein are the private views of the authors and are not to be construed as reflect-ing the views of the FDA.
The article has been copublished in the European Heart Journal, EuroIntervention, Journal of the American College of Cardiology, European Journal of Cardio-Thoracic Surgery, and the Journal of Thoracic and Cardiovascular Surgery.
- ∗
The Valve Academic Research Consortium (VARC) consists of representatives from several independent Academic Research Organizations, several Surgery and Cardiology Societies, members of the US Food and Drug Administration (FDA), and several independent experts. However, it is not a society document. Neither the societies nor the FDA has been asked to endorse the document.